Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bright Minds BiosciencesDRUG +0.04%34 3-Year EPS without NRI Growth Rate is 33.20% as of Jun. 2026, which is at its 10-year median of 33.20. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,157 Biotechnology companies, Bright Minds Biosciences ranks better than 70.44% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 33.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Bright Minds Biosciences was 49.10% per year. The lowest was -74.20% per year. And the median was 33.20% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bright Minds Biosciences 3-Year EPS without NRI Growth Rate Related Terms
DRUG vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Bright Minds Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Bright Minds Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 33.20% mean?
Bright Minds Biosciences (DRUG) has a 3-Year EPS without NRI Growth Rate of 33.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bright Minds Biosciences and its competitors. This is near median its historical median of 33.20. According to the industry distribution chart, Bright Minds Biosciences ranks #342 out of 1157 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Bright Minds Biosciences' 3-Year EPS without NRI Growth Rate too high?
Bright Minds Biosciences' current 3-Year EPS without NRI Growth Rate of 33.20% is near median its 10-year median of 33.20. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Bright Minds Biosciences' value of 33.20% is 108.8% above this industry median. Based on the distribution chart, Bright Minds Biosciences ranks #342 out of 1157 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #342 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This puts Bright Minds Biosciences in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Bright Minds Biosciences' value of 33.20% is 108.8% above this benchmark. While the company's 10-year median is 33.20 vs. the industry median of 15.90, Bright Minds Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bright Minds Biosciences's current 3-Year EPS without NRI Growth Rate of 33.20% is 108.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bright Minds Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current 3-Year EPS without NRI Growth Rate is 33.20%, which is near median its own 10-year median of 33.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current 3-Year EPS without NRI Growth Rate of 33.20%. The current 3-Year EPS without NRI Growth Rate is 33.20%, which is near median its 10-year median of 33.20 and 108.8% above the Biotechnology industry median of 15.90. Bright Minds Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current 3-Year EPS without NRI Growth Rate is 33.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
